SCHEMBL22635693

SCHEMBL22635693

O=C(NCCCl)NC1CCC1

nearest known ligand 0.59

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 15/20 0.59
KDM4E B2RXH2 1/20 0.59
ALDH1A1 P00352 1/20 0.59
EPHX2 P34913 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16060491 0.96 EPHX1 (0.65) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL10254622 0.94 EPHX1 (0.68) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL16058731 0.92 EPHX1 (0.53) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL16059507 0.83 EPHX1 (0.49) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL11700273 0.80 KEAP1 (0.51) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL21855156 0.78 EPHX1 (0.45) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL26677285 0.77 EPHX1 (0.87) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL16059493 0.77 EPHX1 (0.40) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL16059490 0.77 EPHX1 (0.40) EPHX1KDM4EALDH1A1EPHX2
SCHEMBL16059491 0.77 EPHX1 (0.40) EPHX1KDM4EALDH1A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125361-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC (US) 2026-05-07 US disclosed
EP-4480953-B1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC (US) 2026-02-04 EP disclosed
EP-4461734-B1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC (US) 2026-02-04 EP disclosed
US-12351572-B2 Substituted 1,2,4-triazoles as TYK2 inhibitors ALUMIS INC. (US) 2025-07-08 US disclosed
CN-113490664-B TYK2 inhibitors and uses thereof 阿鲁米斯公司 2025-05-16 CN disclosed
EP-4480953-A2 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2024-12-25 EP disclosed
EP-4461734-A2 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2024-11-13 EP disclosed
EP-3870579-B1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC (US) 2024-10-02 EP disclosed
US-12060343-B2 Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors ALUMIS INC. (US) 2024-08-13 US disclosed
US-12006306-B2 Substituted pyridazines as TYK2 inhibitors ALUMIS INC. (US) 2024-06-11 US disclosed
US-20230023761-A1 SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS ALUMIS INC. 2023-01-26 US disclosed
US-20230021554-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2023-01-26 US disclosed
US-20230023761-A1 SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS ALUMIS INC. 2023-01-26 US disclosed
US-20230021554-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2023-01-26 US disclosed
US-20220235035-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2022-07-28 US disclosed
CN-113490664-A TYK2 inhibitors and uses thereof 埃斯克疗法股份有限公司 2021-10-08 CN disclosed
US-11053219-B2 Substituted pyridines as TYK2 inhibitors ESKER THERAPEUTICS, INC. (US) 2021-07-06 US disclosed
US-11053219-B2 Substituted pyridines as TYK2 inhibitors ESKER THERAPEUTICS, INC. (US) 2021-07-06 US disclosed
US-20200354338-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2020-11-12 US disclosed
US-20200354338-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235035-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 EPHX1 3175/4885KDM4E 408/4885ALDH1A1 4098/4885
US-11053219-B2 Substituted pyridines as TYK2 inhibitors TYK2, JAK1, PDXK EPHX1 2261/4885KDM4E 300/4885ALDH1A1 3235/4885
US-20230021554-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 EPHX1 3175/4885KDM4E 408/4885ALDH1A1 4098/4885
US-20230023761-A1 SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS TYK2, JAK1, PDXK EPHX1 2656/4885KDM4E 258/4885ALDH1A1 3600/4885
US-20200354338-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 EPHX1 3175/4885KDM4E 408/4885ALDH1A1 4098/4885
US-12351572-B2 Substituted 1,2,4-triazoles as TYK2 inhibitors TYK2, JAK1, JAK3 EPHX1 3721/4885KDM4E 393/4885ALDH1A1 3054/4885
US-12006306-B2 Substituted pyridazines as TYK2 inhibitors TYK2, PDXK, JAK1 EPHX1 3429/4885KDM4E 283/4885ALDH1A1 3861/4885
US-20260125361-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK3 EPHX1 4520/4885KDM4E 444/4885ALDH1A1 4455/4885
US-12060343-B2 Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors TYK2, JAK1, JAK3 EPHX1 3644/4885KDM4E 577/4885ALDH1A1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.